Can-Fite commences Phase II trial of namodenoson for NAFLD/NASH

Israeli biotechnology firm Can-Fite BioPharma is set to commence patient enrolment for a Phase II clinical trial of namodenoson to treat non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), following the successful conc …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news